By Maria Vogel-Short
New Jersey Law Journal
February 13, 2008
Plaintiffs in New Jersey and six other states who claim the antibiotic Ketek caused liver disease are getting a booster shot from a congressional inquiry into the clinical trials that led to FDA approval.
On Tuesday, witnesses at a hearing before the House Committee on Energy and Commerce’s Subcommittee on Oversight and Investigations testified that Ketek’s trials were flawed and that the company had knowledge of flawed data even before FDA approval.
More than pending ...continue reading...